Equities Analysts Offer Predictions for Janux Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:JANX)

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating) – Research analysts at William Blair issued their Q1 2024 earnings estimates for shares of Janux Therapeutics in a research note issued to investors on Sunday, March 12th. William Blair analyst M. Phipps expects that the company will earn ($0.47) per share for the quarter. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($2.31) per share. William Blair also issued estimates for Janux Therapeutics’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.49) EPS, Q4 2024 earnings at ($0.51) EPS and FY2027 earnings at ($1.83) EPS.

Other equities analysts have also recently issued reports about the stock. TheStreet cut shares of Janux Therapeutics from a “c-” rating to a “d” rating in a research note on Monday, December 12th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Janux Therapeutics in a research note on Monday.

Janux Therapeutics Price Performance

JANX stock opened at $14.36 on Tuesday. The company has a market cap of $598.24 million, a price-to-earnings ratio of -9.45 and a beta of 1.68. The company has a fifty day moving average price of $18.02 and a 200 day moving average price of $15.43. Janux Therapeutics has a 12 month low of $9.39 and a 12 month high of $23.64.

Hedge Funds Weigh In On Janux Therapeutics

Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its stake in shares of Janux Therapeutics by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 47,690 shares of the company’s stock worth $628,000 after purchasing an additional 1,127 shares during the period. American International Group Inc. grew its stake in Janux Therapeutics by 25.3% in the 1st quarter. American International Group Inc. now owns 8,813 shares of the company’s stock valued at $126,000 after acquiring an additional 1,782 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Janux Therapeutics by 21.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 17,934 shares of the company’s stock valued at $257,000 after acquiring an additional 3,186 shares during the last quarter. Bank of America Corp DE grew its stake in Janux Therapeutics by 22.0% in the 4th quarter. Bank of America Corp DE now owns 18,498 shares of the company’s stock valued at $244,000 after acquiring an additional 3,341 shares during the last quarter. Finally, Barclays PLC grew its stake in Janux Therapeutics by 533.0% in the 4th quarter. Barclays PLC now owns 4,608 shares of the company’s stock valued at $61,000 after acquiring an additional 3,880 shares during the last quarter. 70.95% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

(Get Rating)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.